Research status of percutaneous pulmonary valve treatment_West China Medical Journal

Authors：

LI Ruitao ¹ , LI Yijian ² ,  FENG Yuan ²

1. West China School of Medicine, Sichuan University, Chengdu, Sichuan 610041, P. R. China;
2. Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

FENG Yuan, Email: fynotebook@hotmail.com

Keywords：

Percutaneous pulmonary valve treatment; percutaneous balloon pulmonary valvuloplasty; percutaneous pulmonary valve implantation

DOI：

10.7507/1002-0179.202207179

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Nowadays, percutaneous pulmonary valve treatment is a hot topic in valvular heart disease, consisting of percutaneous balloon pulmonary valvuloplasty and percutaneous pulmonary valve implantation (PPVI). The percutaneous balloon pulmonary valvuloplasty is the prime intervention of pulmonary valve stenosis. The main indication of PPVI is pulmonary valve regurgitation and/or obstruction. PPVI is still the research focus, with the improvement of surgical indications and the development of surgical devices. However, compared with surgical pulmonary valve replacement, it still has limitations. This article reviews the treatment progress of percutaneous pulmonary valve treatment, especially PPVI.

Citation： LI Ruitao, LI Yijian, FENG Yuan. Research status of percutaneous pulmonary valve treatment. West China Medical Journal, 2022, 37(9): 1293-1298. doi: 10.7507/1002-0179.202207179 Copy

1.	Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet, 2000, 356(9239): 1403-1405.
2.	Apitz C, Webb GD, Redington A. Tetralogy of Fallot. Lancet, 2009, 374(9699): 1462-1471.
3.	Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J, 2021, 42(6): 563-645.
4.	Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2019, 73(12): e81-e192.
5.	Peterson C, Schilthuis JJ, Dodge-Khatami A, et al. Comparative long-term results of surgery versus balloon valvuloplasty for pulmonary valve stenosis in infants and children. Ann Thorac Surg, 2003, 76(4): 1078-1082.
6.	Santoro G, Formigari R, Di Carlo D, et al. Midterm outcome after pulmonary balloon valvuloplasty in patients younger than one year of age. Am J Cardiol, 1995, 75(8): 637-639.
7.	Hong D, Qian MY, Zhang ZW, et al. Immediate therapeutic outcomes and medium-term follow-up of percutaneous balloon pulmonary valvuloplasty in infants with pulmonary valve stenosis: a single-center retrospective study. Chin Med J (Engl), 2017, 130(23): 2785-2792.
8.	Schievano S, Coats L, Migliavacca F, et al. Variations in right ventricular outflow tract morphology following repair of congenital heart disease: implications for percutaneous pulmonary valve implantation. J Cardiovasc Magn Reson, 2007, 9(4): 687-695.
9.	Capelli C, Taylor AM, Migliavacca F, et al. Patient-specific reconstructed anatomies and computer simulations are fundamental for selecting medical device treatment: application to a new percutaneous pulmonary valve. Philos Trans A Math Phys Eng Sci, 2010, 368(1921): 3027-3038.
10.	Buber J, Assenza GE, Huang A, et al. Durability of large diameter right ventricular outflow tract conduits in adults with congenital heart disease. Int J Cardiol, 2014, 175(3): 455-463.
11.	Kheiwa A, Divanji P, Mahadevan VS. Transcatheter pulmonary valve implantation: will it replace surgical pulmonary valve replacement?. Expert Rev Cardiovasc Ther, 2018, 16(3): 197-207.
12.	Cheatham JP, Hellenbrand WE, Zahn EM, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation, 2015, 131(22): 1960-1970.
13.	Shahanavaz S, Zahn EM, Levi DS, et al. Transcatheter pulmonary valve replacement with the sapien prosthesis. J Am Coll Cardiol, 2020, 76(24): 2847-2858.
14.	Shahanavaz S, Balzer D, Babaliaros V, et al. Alterra adaptive prestent and SAPIEN 3 THV for congenital pulmonic valve dysfunction: an early feasibility study. JACC Cardiovasc Interv, 2020, 13(21): 2510-2524.
15.	Bergersen L, Benson LN, Gillespie MJ, et al. Harmony feasibility trial: acute and short-term outcomes with a self-expanding transcatheter pulmonary valve. JACC Cardiovasc Interv, 2017, 10(17): 1763-1773.
16.	Zhou D, Pan W, Jilaihawi H, et al. A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results. EuroIntervention, 2019, 14(13): 1371-1377.
17.	Shang X, Dong N, Zhang C, et al. The clinical trial outcomes of Med-Zenith PT-valve in the treatment of patients with severe pulmonary regurgitation. Front Cardiovasc Med, 2022, 9: 887886.
18.	Kim GB, Song MK, Bae EJ, et al. Successful feasibility human trial of a new self-expandable percutaneous pulmonary valve (Pulsta Valve) implantation using knitted nitinol wire backbone and trileaflet α-gal-free porcine pericardial valve in the native right ventricular outflow tract. Circ Cardiovasc Interv, 2018, 11(6): e006494.
19.	Ribeiro JM, Teixeira R, Lopes J, et al. Transcatheter versus surgical pulmonary valve replacement: a systemic review and meta-analysis. Ann Thorac Surg, 2020, 110(5): 1751-1761.
20.	Zhou Y, Xiong T, Bai P, et al. Clinical outcomes of transcatheter versus surgical pulmonary valve replacement: a meta-analysis. J Thorac Dis, 2019, 11(12): 5343-5351.
21.	McElhinney DB, Sondergaard L, Armstrong AK, et al. Endocarditis after transcatheter pulmonary valve replacement. J Am Coll Cardiol, 2018, 72(22): 2717-2728.
22.	McElhinney DB, Zhang Y, Aboulhosn JA, et al. Multicenter study of endocarditis after transcatheter pulmonary valve replacement. J Am Coll Cardiol, 2021, 78(6): 575-589.
23.	Nordmeyer J, Ewert P, Gewillig M, et al. Acute and midterm outcomes of the post-approval MELODY Registry: a multicentre registry of transcatheter pulmonary valve implantation. Eur Heart J, 2019, 40(27): 2255-2264.
24.	Alassas K, Mohty D, Clavel MA, et al. Transcatheter versus surgical valve replacement for a failed pulmonary homograft in the Ross population. J Thorac Cardiovasc Surg, 2018, 155(4): 1434-1444.
25.	Li WF, Pollard H, Karimi M, et al. Comparison of valvar and right ventricular function following transcatheter and surgical pulmonary valve replacement. Congenit Heart Dis, 2018, 13(1): 140-146.
26.	McElhinney DB, Zhang Y, Levi DS, et al. Reintervention and survival after transcatheter pulmonary valve replacement. J Am Coll Cardiol, 2022, 79(1): 18-32.
27.	Bokma JP, Winter MM, Oosterhof T, et al. Individualised prediction of pulmonary homograft durability in tetralogy of Fallot. Heart, 2015, 101(21): 1717-1723.
28.	Kwak JG, Bang JH, Cho S, et al. Long-term durability of bioprosthetic valves in pulmonary position: pericardial versus porcine valves. J Thorac Cardiovasc Surg, 2020, 160(2): 476-484.

1. Bonhoeffer P, Boudjemline Y, Saliba Z, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet, 2000, 356(9239): 1403-1405.
2. Apitz C, Webb GD, Redington A. Tetralogy of Fallot. Lancet, 2009, 374(9699): 1462-1471.
3. Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J, 2021, 42(6): 563-645.
4. Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2019, 73(12): e81-e192.
5. Peterson C, Schilthuis JJ, Dodge-Khatami A, et al. Comparative long-term results of surgery versus balloon valvuloplasty for pulmonary valve stenosis in infants and children. Ann Thorac Surg, 2003, 76(4): 1078-1082.
6. Santoro G, Formigari R, Di Carlo D, et al. Midterm outcome after pulmonary balloon valvuloplasty in patients younger than one year of age. Am J Cardiol, 1995, 75(8): 637-639.
7. Hong D, Qian MY, Zhang ZW, et al. Immediate therapeutic outcomes and medium-term follow-up of percutaneous balloon pulmonary valvuloplasty in infants with pulmonary valve stenosis: a single-center retrospective study. Chin Med J (Engl), 2017, 130(23): 2785-2792.
8. Schievano S, Coats L, Migliavacca F, et al. Variations in right ventricular outflow tract morphology following repair of congenital heart disease: implications for percutaneous pulmonary valve implantation. J Cardiovasc Magn Reson, 2007, 9(4): 687-695.
9. Capelli C, Taylor AM, Migliavacca F, et al. Patient-specific reconstructed anatomies and computer simulations are fundamental for selecting medical device treatment: application to a new percutaneous pulmonary valve. Philos Trans A Math Phys Eng Sci, 2010, 368(1921): 3027-3038.
10. Buber J, Assenza GE, Huang A, et al. Durability of large diameter right ventricular outflow tract conduits in adults with congenital heart disease. Int J Cardiol, 2014, 175(3): 455-463.
11. Kheiwa A, Divanji P, Mahadevan VS. Transcatheter pulmonary valve implantation: will it replace surgical pulmonary valve replacement?. Expert Rev Cardiovasc Ther, 2018, 16(3): 197-207.
12. Cheatham JP, Hellenbrand WE, Zahn EM, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation, 2015, 131(22): 1960-1970.
13. Shahanavaz S, Zahn EM, Levi DS, et al. Transcatheter pulmonary valve replacement with the sapien prosthesis. J Am Coll Cardiol, 2020, 76(24): 2847-2858.
14. Shahanavaz S, Balzer D, Babaliaros V, et al. Alterra adaptive prestent and SAPIEN 3 THV for congenital pulmonic valve dysfunction: an early feasibility study. JACC Cardiovasc Interv, 2020, 13(21): 2510-2524.
15. Bergersen L, Benson LN, Gillespie MJ, et al. Harmony feasibility trial: acute and short-term outcomes with a self-expanding transcatheter pulmonary valve. JACC Cardiovasc Interv, 2017, 10(17): 1763-1773.
16. Zhou D, Pan W, Jilaihawi H, et al. A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results. EuroIntervention, 2019, 14(13): 1371-1377.
17. Shang X, Dong N, Zhang C, et al. The clinical trial outcomes of Med-Zenith PT-valve in the treatment of patients with severe pulmonary regurgitation. Front Cardiovasc Med, 2022, 9: 887886.
18. Kim GB, Song MK, Bae EJ, et al. Successful feasibility human trial of a new self-expandable percutaneous pulmonary valve (Pulsta Valve) implantation using knitted nitinol wire backbone and trileaflet α-gal-free porcine pericardial valve in the native right ventricular outflow tract. Circ Cardiovasc Interv, 2018, 11(6): e006494.
19. Ribeiro JM, Teixeira R, Lopes J, et al. Transcatheter versus surgical pulmonary valve replacement: a systemic review and meta-analysis. Ann Thorac Surg, 2020, 110(5): 1751-1761.
20. Zhou Y, Xiong T, Bai P, et al. Clinical outcomes of transcatheter versus surgical pulmonary valve replacement: a meta-analysis. J Thorac Dis, 2019, 11(12): 5343-5351.
21. McElhinney DB, Sondergaard L, Armstrong AK, et al. Endocarditis after transcatheter pulmonary valve replacement. J Am Coll Cardiol, 2018, 72(22): 2717-2728.
22. McElhinney DB, Zhang Y, Aboulhosn JA, et al. Multicenter study of endocarditis after transcatheter pulmonary valve replacement. J Am Coll Cardiol, 2021, 78(6): 575-589.
23. Nordmeyer J, Ewert P, Gewillig M, et al. Acute and midterm outcomes of the post-approval MELODY Registry: a multicentre registry of transcatheter pulmonary valve implantation. Eur Heart J, 2019, 40(27): 2255-2264.
24. Alassas K, Mohty D, Clavel MA, et al. Transcatheter versus surgical valve replacement for a failed pulmonary homograft in the Ross population. J Thorac Cardiovasc Surg, 2018, 155(4): 1434-1444.
25. Li WF, Pollard H, Karimi M, et al. Comparison of valvar and right ventricular function following transcatheter and surgical pulmonary valve replacement. Congenit Heart Dis, 2018, 13(1): 140-146.
26. McElhinney DB, Zhang Y, Levi DS, et al. Reintervention and survival after transcatheter pulmonary valve replacement. J Am Coll Cardiol, 2022, 79(1): 18-32.
27. Bokma JP, Winter MM, Oosterhof T, et al. Individualised prediction of pulmonary homograft durability in tetralogy of Fallot. Heart, 2015, 101(21): 1717-1723.
28. Kwak JG, Bang JH, Cho S, et al. Long-term durability of bioprosthetic valves in pulmonary position: pericardial versus porcine valves. J Thorac Cardiovasc Surg, 2020, 160(2): 476-484.

Previous Article
Complications and management of transcatheter edge-to-edge mitral valve repair
Next Article
Peri-interventional echo assessment for transcatheter edge-to-edge repair

West China Medical Journal

Research status of percutaneous pulmonary valve treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content